Different patterns of NT-proBNP secretion in acute coronary syndromes

Clinica Chimica Acta

Volumn 402, Issue 1-2, 2009, Pages 176-181

  Ferraro, Simona ^a   Lupi, Alessandro ^a   Marano, Giuseppe ^b   Rossi, Lidia ^a   Ciardi, Laura ^a   Vendramin, Chiara ^a   Bellomo, Giorgio ^a   Boracchi, Patrizia ^b   Bongo, Angelo Sante ^a   Biganzoli, Elia ^b  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Acute coronary syndrome; Kinetic; Natriuretic peptides; Secretory pattern

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CHROMOGRANIN A; CREATININE; CYSTATIN C;

ACUTE CORONARY SYNDROME; ADRENERGIC STIMULATION; ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GLOMERULUS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST ELEVATION ACUTE CORONARY SYNDROME; PRIORITY JOURNAL; PROTEIN SECRETION; ST ELEVATION ACUTE CORONARY SYNDROME; SYMPTOMATOLOGY;

ACUTE CORONARY SYNDROME; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHROMOGRANIN A; CYSTATIN C; FEMALE; HUMANS; KINETICS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 60649115811     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.01.005     Document Type: Article

References (28)

1. Clerico A. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: is their assay merely a marker of cardiac disease?. Clin Chem Lab Med 40 (2002) 752-760
2. Clerico A., Iervasi G., and Pilo A. Turnover studies on cardiac natriuretic peptides: methodological, pathophysiological and therapeutical considerations. Curr Drug Metab 1 (2000) 85-105
3. Pagani F., Stefini F., and Panteghini M. Biological variation in serum concentrations of N-terminal pro-brain natriuretic peptide(NT-proBNP). Clin Chem 49 (2003) A34
4. D'Souza S.P., Yellon D.M., Martin C., et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 284 (2003) H 1592-H 1600
5. Goetze J.P., Christoffersen C., Perko M., et al. Increased BNP cardiac expression associated with myocardial ischemia. FASEB J 17 (2003) 1105-1107
6. Hama N., Itoh H., Shirakami G., et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 92 (1995) 1558-1564
7. Goetze J.P., Gore A., Møller C.H., Steinbrüchel D.A., Rehfeld J.F., and Nielsen L.B. Acute myocardial hypoxia increases BNP gene expression. FASEB J 18 (2004) 1928-1930
8. Morita E., Yasue H., Yoshimura M., et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88 (1993) 82-91
9. Luchner A., Hengstenberdg C., Löwel H., et al. NT-ProBNP in outpatients after myocardial infarction: interaction between symptoms and left ventricular function and optimized cut-points. J Card Fail 11 (2005) S 21-S 27
10. James S.K., Lindhal B., Siegbahn A., et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies to Open occluded arteries(GUSTO)-IV substudy. Circulation 108 (2003) 275-281
11. Jernberg T., Stridberg M., Venge P., et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 40 (2002) 437-445
12. Omland T., Persson A., O'Brien L., et al. N-terminal pro-B type natriuretic peptide and long term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918
13. Heeschen C., Hamm C., Mitrovic V., Lantelme N.H., and White H.D. N-Terminal pro-BType natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110 (2004) 3206-3212
14. Wang J., Sim A.S., Wang X.L., Salonikas C., et al. Relation between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease. Atherosclerosis 197 (2008) 853-859
15. Vahid-Ansari F., and Leenen F.H.H. Pattern of neuronal activation in rats with CHF after myocardial infarction. Am J Physiol Heart Circ Physiol 275 (1998) H 2140-H 2146
16. Hojs R., Bevc S., Antolinc B., Gorenjak M., and Puklavec L. Serum Cystatin C as an endogenous marker of renal function in the elderly. Int J Pharmacol Res 24 (2004) 49-54
17. Mussap M., Dalla Vestra M., Fioretto P., et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 61 (2002) 1453-1461
18. O'Connor D.T., and Frigon R.P. Chromogranin A the major cathecolamine storage vesicle soluble protein. J Biol Chem 259 (1984) 3237-3247
19. Cryer P.E., Wortsman J., Shah S.D., Nowak R.M., and Deftos L.J. Plasma Chromogranin A as a marker of sympathochromaffin activity in humans. Am J Physiol 260 (1991) E 243-E 246
20. Thygesen K., Alpert J.S., White H.D., et al. on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the redefinition of myocardial infarction. Universal definition of myocardial infarction. Eur Heart J 28 (2007) 2525-2538
21. Apple F.S., Smith S.W., Pearce L.A., Ranka L., and Mutakami M.M. Use of Centaur TnI-Ultra assay for detection of myocardial infarction and adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 54 (2008) 723-728
22. De Filippi C.R., Seliger S.L., Maynard S., and Christenson R.H. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem 53 (2007) 1511-1519
23. Harrell Jr. F.E. Regression Modeling Strategies (2001), Springer
24. Cryer P.E., Wortsman J., Shah S.D., Nowak R.M., and Deftos L.J. Plasma chromogranin A as a marker of sympathochromaffin activity in humans. Am J Physiol 260 (1991) E243-E246
25. Estensen M.E., Hognestad A., Syversen U., et al. Prognostic value of plasma Chromogranin A levels in patients with complicated myocardial infarction. Am Heart J 152 (2006) e1-e6
26. Body R., and Roberts C. Brain natriuretic peptide as a potential marker of acute coronary syndromes. Emerg Med J 23 (2006) 403-407
27. Jarai R., Wojta J., and Huber K. Circulating B-type natriuretic peptides in patients with acute coronary syndromes. pathophysiological, prognostical and therapeutical considerations. Thromb Haemost 94 (2005) 926-932
28. Omland T. Clinical and laboratory diagnostics of cardiovascular disease: focus on natriuretic peptides and cardiac ischemia. Scand J Clin Lab Invest Suppl 240 (2005) 18-24